Clinical Manifestations and Outcomes of 20 Korean Hypochondroplasia Patients with the FGFR3 N540K variant

Abstract

Background Hypochondroplasia is a skeletal dysplasia caused by activating pathologic variants of FGFR3. The N540K variant accounts for 60–70% of reported cases and is associated with severe manifestations. Here, we analyze the clinical manifestations and outcomes of Korean patients with hypochondroplasia harboring the FGFR3 N540K variant.

Methods Medical records of 20 unrelated patients with genetically confirmed N540K-related hypochondroplasia were retrospectively reviewed. All individuals were diagnosed with hypochondroplasia by Sanger sequencing for FGFR3, or target-panel sequencing for skeletal dysplasia. The effectiveness of growth hormone therapy was analyzed in 16 patients treated with growth hormones.

Results Among 20 patients (7 men, 13 women), the mean age at first visit was 3.5±1.0 years, and the mean follow-up duration was 6.8±0.6 years. The patients presented with a short stature and/or short limbs. Genu varum, macrocephaly, and developmental delay were observed in 11 (55.0%), 9 (45.0%), and 5 (25.0%) patients, respectively. Of the 12 patients who underwent neuroimaging, five (41.7%) showed abnormal findings (one required operation for obstructive hydrocephalus). Among 16 growth-hormone-treated patients (two were growth-hormone deficient), the increase in height standard deviation scores was significant after a mean 5.4±0.7 years of treatment (+0.6 and+1.8 using growth references for healthy controls and achondroplasia children, respectively). Four patients underwent surgical limb lengthening at a mean age of 8.8±3.3 years.

Conclusions Neurodevelopmental abnormalities are frequently observed in patients with N540K-related hypochondroplasia. Close monitoring of skeletal manifestations and neurodevelopmental status is necessary for hypochondroplasia.

Key words

hypochondroplasia - skeletal dysplasia - fibroblast growth factor receptor-3 - Korean

Publication History

Received: 06 May 2022
Received: 12 November 2022

Accepted: 28 November 2022

Accepted Manuscript online:
28 November 2022

Article published online:
14 February 2023

• References

• 1 Bober MB, Bellus GA, Nikkel SM. et al. Hypochondroplasia. In: GeneReviews [Internet]. Seattle (WA). University of Washington; Seattle: 1999: 1993-2022
• 2 Du X, Xie Y, Xian CJ. et al. Role of FGFs/FGFRs in skeletal development and bone regeneration. J Cell Physiol 2012; 227: 3731-3743 DOI: 10.1002/jcp.24083.
• 3 Bellus GA, McIntosh I, Smith EA. et al. A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia. Nat Genet 1995; 10: 357-359 DOI: 10.1038/ng0795-357.
• 4 Prinos P, Costa T, Sommer A. et al. A common FGFR3 gene mutation in hypochondroplasia. Hum Mol Genet 1995; 4: 2097-2101 DOI: 10.1093/hmg/4.11.2097.
• 5 Bonaventure J, Rousseau F, Legeai-Mallet L. et al. Common mutations in the fibroblast growth factor receptor 3 (FGFR 3) gene account for achondroplasia, hypochondroplasia, and thanatophoric dwarfism. Am J Med Genet 1996; 63: 148-154 DOI: 10.1002/(SICI)1096-8628(19960503)63:1<148::AID-AJMG26>3.0.CO;2-N.
• 6 Wynne-Davies R, Patton MA. The frequency of mental retardation in hypochondroplasia. J Med Genet 1991; 28: 644 DOI: 10.1136/jmg.28.9.644.
• 7 Linnankivi T, Makitie O, Valanne L. et al. Neuroimaging and neurological findings in patients with hypochondroplasia and FGFR3 N540K mutation. Am J Med Genet A 2012; 158A: 3119-3125 DOI: 10.1002/ajmg.a.35642.
• 8 Panda A, Gamanagatti S, Jana M. et al. Skeletal dysplasias: a radiographic approach and review of common non-lethal skeletal dysplasias. World J Radiol 2014; 6: 808-825 DOI: 10.4329/wjr.v6.i10.808.
• 9 Sargar KM, Singh AK, Kao SC. Imaging of skeletal disorders caused by fibroblast growth factor receptor gene mutations. Radiographics 2017; 37: 1813-1830 DOI: 10.1148/rg.2017170017.
• 10 Pinto G, Cormier-Daire V, Le Merrer M. et al. Efficacy and safety of growth hormone treatment in children with hypochondroplasia: comparison with an historical cohort. Horm Res Paediatr 2014; 82: 355-363 DOI: 10.1159/000364807.
• 11 Rothenbuhler A, Linglart A, Piquard C. et al. A pilot study of discontinuous, insulin-like growth factor 1-dosing growth hormone treatment in young children with FGFR3 N540K-mutated hypochondroplasia. J Pediatr 2012; 160: 849-853 DOI: 10.1016/j.jpeds.2011.10.023.
• 12 Çetin T, Şıklar Z, Kocaay P. et al. Evaluation of Efficacy of Long-term Growth Hormone Therapy in Patients with Hypochondroplasia. J Clin Res Pediatr Endocrinol 2018; 10: 373-376 DOI: 10.4274/jcrpe.0043.
• 13 Grigelioniené G, Eklöf O, Laurencikas E. et al. Asn540Lys mutation in fibroblast growth factor receptor 3 and phenotype in hypochondroplasia. Acta Paediatr 2000; 89: 1072-1076 DOI: 10.1080/713794579.
• 14 Rousseau F, Bonaventure J, Legeai-Mallet L. et al. Clinical and genetic heterogeneity of hypochondroplasia. J Med Genet 1996; 33: 749-752 DOI: 10.1136/jmg.33.9.749.
• 15 Prinster C, Carrera P, Del Maschio M. et al. Comparison of clinical-radiological and molecular findings in hypochondroplasia. Am J Med Genet 1998; 75: 109-112 DOI: 10.1002/(sici)1096-8628(19980106)75:1<109::aid-ajmg22>3.0.co;2-p.
• 16 Ramaswami U, Rumsby G, Hindmarsh PC. et al. Genotype and phenotype in hypochondroplasia. J Pediatr 1998; 133: 99-102 DOI: 10.1016/s0022-3476(98)70186-6.
• 17 Shin Y-L, Choi J-H, Kim G-H. et al. Comparison of clinical, radiological and molecular findings in Korean infants and children with achondroplasia and hypochondroplasia. J Pediatr Endocrinol Metab 2005; 18: 999-1005 DOI: 10.1515/jpem.2005.18.10.999.
• 18 Song S-H, Balce GCE, Agashe MV. et al. New proposed clinico-radiologic and molecular criteria in hypochondroplasia: FGFR 3 gene mutations are not the only cause of hypochondroplasia. Am J Med Genet A 2012; 158A: 2456-2462 DOI: 10.1002/ajmg.a.35564.
• 19 Fenton TR, Kim JH. A systematic review and meta-analysis to revise the Fenton growth chart for preterm infants. BMC Pediatr 2013; 13: 59 DOI: 10.1186/1471-2431-13-59.
• 20 Kim JH, Yun S, Hwang S-S. et al. The 2017 Korean National Growth Charts for children and adolescents: development, improvement, and prospects. Korean J Pediatr 2018; 61: 135-149 DOI: 10.3345/kjp.2018.61.5.135.
• 21 Hoover-Fong J, McGready J, Schulze K. et al. A height-for-age growth reference for children with achondroplasia: expanded applications and comparison with original reference data. Am J Med Genet A 2017; 173: 1226-1230 DOI: 10.1002/ajmg.a.38150.
• 22 Cohen P, Rogol AD, Deal CL. et al. Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. J Clin Endocrinol Metab 2008; 93: 4210-4217 DOI: 10.1210/jc.2008-0509.
• 23 Accogli A, Geraldo AF, Piccolo G. et al. Diagnostic Approach to Macrocephaly in Children. Front Pediatr 2022; 9: 794069 DOI: 10.3389/fped.2021.794069.
• 24 Tanner JM, Goldstein H, Whitehouse RH. Standards for children’s height at ages 2-9 years allowing for heights of parents. Arch Dis Child 1970; 45: 755-762 DOI: 10.1136/adc.45.244.755.
• 25 Quanjer PH, Capderou A, Mazicioglu MM. et al. All-age relationship between arm span and height in different ethnic groups. Eur Respir J 2014; 44: 905-912 DOI: 10.1183/09031936.00054014.
• 26 Matsui Y, Yasui N, Kimura T. et al. Genotype phenotype correlation in achondroplasia and hypochondroplasia. J Bone Joint Surg Br 1998; 80: 1052-1056 DOI: 10.1302/0301-620x.80b6.9277.
• 27 Scharf RJ, Scharf GJ, Stroustrup A. Developmental Milestones. Pediatr Rev 2016; 37: 25-37 quiz 38, 47 DOI: 10.1542/pir.2014-0103.
• 28 Hyun SE, Lee BC, Suh BK. et al. Reference values for serum levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in Korean children and adolescents. Clin Biochem 2012; 45: 16-21 DOI: 10.1016/j.clinbiochem.2011.10.003.
• 29 Tanner JM, Whitehouse RH, Takaishi M. Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children, 1965. I. Arch Dis Child 1966; 41: 454-471 DOI: 10.1136/adc.41.219.454.
• 30 Saito T, Nagasaki K, Nishimura G. et al. Radiological clues to the early diagnosis of hypochondroplasia in the neonatal period: report of two patients. Am J Med Genet A 2012; 158A: 630-634 DOI: 10.1002/ajmg.a.34424.
• 31 Sabir AH, Sheikh J, Singh A. et al. Earlier detection of hypochondroplasia: a large single-center UK case series and systematic review. Am J Med Genet A 2021; 185: 73-82 DOI: 10.1002/ajmg.a.61912.
• 32 Walker BA, Murdoch JL, McKusick VA. et al. Hypochondroplasia. Am J Dis Child 1971; 122: 95-104 DOI: 10.1001/archpedi.1971.02110020029001.
• 33 Hall BD, Spranger J. Hypochondroplasia: clinical and radiological aspects in 39 cases. Radiology 1979; 133: 95-100 DOI: 10.1148/133.1.95.
• 34 Grosso S, Farnetani MA, Berardi R. et al. Medial temporal lobe dysgenesis in Muenke syndrome and hypochondroplasia. Am J Med Genet A 2003; 120A: 88-91 DOI: 10.1002/ajmg.a.10171.
• 35 Kannu P, Hayes IM, Mandelstam S. et al. Medial temporal lobe dysgenesis in hypochondroplasia. Am J Med Genet A 2005; 138: 389-391 DOI: 10.1002/ajmg.a.30974.
• 36 Kannu P, Aftimos S. FGFR3 mutations and medial temporal lobe dysgenesis. J Child Neurol 2007; 22: 211-213 DOI: 10.1177/0883073807300292.
• 37 Okazaki T, Saito Y, Ueda R. et al. Epileptic phenotype of FGFR3-related bilateral medial temporal lobe dysgenesis. Brain Dev 2017; 39: 67-71 DOI: 10.1016/j.braindev.2016.07.004.
• 38 Moldrich RX, Mezzera C, Holmes WM. et al. Fgfr3 regulates development of the caudal telencephalon. Dev Dyn 2011; 240: 1586-1599 DOI: 10.1002/dvdy.22636.
• 39 Appan S, Laurent S, Chapman M. et al. Growth and growth hormone therapy in hypochondroplasia. Acta Paediatr Scand 1990; 79: 796-803 DOI: 10.1111/j.1651-2227.1990.tb11557.x.
• 40 Bridges NA, Hindmarsh PC, Brook CG. Growth of children with hypochondroplasia treated with growth hormone for up to three years. Horm Res 1991; 36: 56-60 DOI: 10.1159/000182190.
• 41 Tanaka N, Katsumata N, Horikawa R. et al. The comparison of the effects of short-term growth hormone treatment in patients with achondroplasia and with hypochondroplasia. Endocr J 2003; 50: 69-75 DOI: 10.1507/endocrj.50.69.
• 42 Massart F, Miccoli M, Baggiani A. et al. Height outcome of short children with hypochondroplasia after recombinant human growth hormone treatment: a meta-analysis. Pharmacogenomics 2015; 16: 1965-1973 DOI: 10.2217/pgs.15.129.
• 43 Legeai-Mallet L. C-type natriuretic peptide analog as therapy for achondroplasia. Endocr Dev 2016; 30: 98-105 DOI: 10.1159/000439334.
• 44 Meyer MF, Menken KU, Zimny S. et al. Pitfall in diagnosing growth hormone deficiency in a hypochondroplastic patient with a delayed puberty. Exp Clin Endocrinol Diabetes 2003; 111: 177-181 DOI: 10.1055/s-2003-39780.